How Sponsors And CROs Can Fully Benefit From The Permanent Shift To Decentralized Home-Visit Clinical Trials

Evidence is mounting that hybrid and decentralized clinical trials are here to stay. What was once a nice-to-have is quickly transforming into a must-have. As reported in Clinical Trials Arena ¹, roughly 1,300 clinical trials with a virtual and/or decentralized component will begin in 2022, representing a 93% increase over 2020. And in a recent Industry Standard Research (ISR) survey ² of clinical trial sponsors and CROs, more than 80% of respondents said they expect the hybrid model to be used more often than the traditional trial model within the next three years. The catalyst for this dramatic shift was the COVID-19 pandemic when, to avoid over-burdening hospitals and healthcare facilities, many non-essential clinical trials were deferred.³

To aid sponsors and CROs in fully realizing the benefits of decentralized clinical trial methods moving forward, this whitepaper extracts the lessons learned from the pandemic and their implications for clinical trials now and in the future.